- Market Realist•2 hours ago
Vimizim is BioMarin’s (BMRN) lead drug. It earned $179.4 million in the first six months of 2016, which is a 71.7% increase over the first half of 2015.
- Market Realist•21 hours ago
During its 2Q16 earnings call, BioMarin revised its 2016 revenue guidance. It now expects revenue to be $1.1 billion–$1.15 billion.
BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||95.33 x 100|
|Ask||95.50 x 200|
|Day's Range||94.42 - 96.26|
|52wk Range||62.12 - 136.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-29.08|
|Avg Vol (3m)||1,919,379|
|Dividend & Yield||N/A (N/A)|